Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95

Leukemia

Volumn 31, Issue 8, 2017, Pages 1840-1842

  Hinze, L ^a   Moricke A ^b   Zimmermann, M ^a   Junk, S ^a   Cario, G ^b   Dagdan, E ^a   Kratz, C P ^a   Conter, V ^c   Schrappe, M ^b   Stanulla, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DEXAMETHASONE; IKAROS TRANSCRIPTION FACTOR; IKAROS TRANSCRIPTION FACTOR 1; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; IKZF1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; DRUG PULSE THERAPY; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; GENETIC ASSOCIATION; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; ADOLESCENT; GENETICS; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; GENE DELETION; HUMANS; IKAROS TRANSCRIPTION FACTOR; MERCAPTOPURINE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 85026638261     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.154     Document Type: Letter

References (10)

1. Vrooman LM, Silverman LB. Treatment of childhood acute lymphoblastic leukemia: prognostic factors and clinical advances. Curr Hematol Malig Rep 2016; 11: 385-394.
2. Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 2016; 101: 407-416.
3. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
4. Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bourqin J-P et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013; 98: 428-432.
5. van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, te Kronnie G, Harrison C-J et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 23 (11): 1691-1698.
6. Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Childrens Leukemia Group study 58951. Leukemia 2015; 29: 2154-2161.
7. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymhoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2009; 113: 4478.
8. Conter V, Valsecchi MG, Campbell M, Dibar E, Magyarosy E, Gadner H et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369: 123-131.
9. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V et al. Breakpointspecific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell acute lymphoblastic leukemia. Haematologica 2013; 98: 597-601.
10. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.